Gilead Sciences acquired MYR GmbH for ~EUR 1.3 billion (~$1.6 billion), a transaction announced in March 2021.
Acquired the German biotechnology company for its chronic hepatitis delta virus (HDV) treatment Hepcludex (bulevirtide), conditionally approved by the EMA. Aggregate consideration of EUR 1.3 billion (~$1.6 billion), including ~EUR 1.0 billion (~$1.2 billion) paid on closing plus contingent consideration.
Acquired the German biotechnology company for its chronic hepatitis delta virus (HDV) treatment Hepcludex (bulevirtide), conditionally approved by the EMA. Aggregate consideration of EUR 1.3 billion (~$1.6 billion), including ~EUR 1.0 billion (~$1.2 billion) paid on closing plus contingent consideration.
Advisory firms were not disclosed for this transaction.